GabatheAB announced that it has received approval from the JPO for the national phase patent application No. 2020 -554957. The invention relates to the synthesis and production of triazoloquinazolinones and is based on the PCT International Application No.

PCT/IB2018/001573. The invention expands position in the field of GABAA receptor modulators and medical use. This patent together with patent portfolio covers key products and methods that creates substantial value to the company and shareholders, giving Gabather both the freedom to operate and important differentiation of products.